Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFD | P00746 | 1/20 | 0.41 |
| ▸ | KARS1 | Q15046 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 2/20 | 0.38 |
| ▸ | KDR | P35968 | 7/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.37 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.36 |
| ▸ | CAMK2D | Q13557 | 2/20 | 0.35 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.35 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.35 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.35 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.35 |
| ▸ | IDH1 | O75874 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5914205 | 0.91 | CFD (0.39) | CFDSYKKDRMAPK14DYRK1B | |
| SCHEMBL5266372 | 0.90 | EPHB4 (0.44) | KDRMAPK14DYRK1BEPHB4 | |
| SCHEMBL5913862 | 0.89 | CFD (0.39) | CFDSYKKDRMAPK14MAPK13 | |
| SCHEMBL5913846 | 0.86 | HRH4 (0.38) | CFDKARS1SYKKDRMAPK14 | |
| SCHEMBL5312144 | 0.83 | CFD (0.35) | CFDSYKKDRMAPK14DYRK1B | |
| SCHEMBL6417723 | 0.83 | CFD (0.34) | CFDKARS1SYKKDRMAPK14 | |
| SCHEMBL5262710 | 0.81 | EPHB4 (0.42) | KDRMAPK14DYRK1BCAMK2DEPHB4 | |
| SCHEMBL5913998 | 0.81 | EPHB4 (0.42) | KDRMAPK14DYRK1BCAMK2DEPHB4 | |
| SCHEMBL5914143 | 0.81 | SMN1; SMN2 (0.39) | CFDKARS1SYKKDRMAPK14 | |
| SCHEMBL5914222 | 0.81 | DYRK1B (0.38) | CFDSYKKDRMAPK14DYRK1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060069110-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069110-A1 | Substituted heterocyclic compounds and methods of use | MAPT, MYLK2, IAPP | CFD 4289/4885KARS1 1996/4885SYK 1478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.